Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The New Political Economy of PharmaceuticalsThe Pharmaceutical Industry in India after TRIPS

The New Political Economy of Pharmaceuticals: The Pharmaceutical Industry in India after TRIPS [The Indian pharmaceutical industry occupies a special position among developing countries.1 It has demonstrated strong innovation capabilities, tremendous strength in developing cost-efficient processes and significant capacity in setting up manufacturing plants for drugs satisfying international quality norms. India supplies medicines not only to other developing countries but also to developed countries such as the US. One of the most important factors contributing to this remarkable development was the abolition of product patent protection for pharmaceuticals in 1972. After independence, wanting to develop a pharmaceutical industry, India had invited multinational corporations (MNCs) to help develop the industry. Before 1972, although not keen to manufacture pharmaceuticals in India, they had used their patent rights to prevent Indian companies from doing so. As a result, in this period the industry remained underdeveloped, while at the same time multinationals’ monopolies led to high prices.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

The New Political Economy of PharmaceuticalsThe Pharmaceutical Industry in India after TRIPS

Part of the International Political Economy Series Book Series
Editors: Löfgren, Hans; Williams, Owain David
Chaudhuri, Sudip
The New Political Economy of Pharmaceuticals — Nov 6, 2015
Download PDF
22 pages

Loading next page...
 
/lp/springer-journals/the-new-political-economy-of-pharmaceuticals-the-pharmaceutical-Riq7voaeGy
Publisher
Palgrave Macmillan UK
Copyright
© Palgrave Macmillan, a division of Macmillan Publishers Limited 2013
ISBN
978-1-349-32976-2
Pages
111 –133
DOI
10.1057/9781137315854_6
Publisher site
See Chapter on Publisher Site

Abstract

[The Indian pharmaceutical industry occupies a special position among developing countries.1 It has demonstrated strong innovation capabilities, tremendous strength in developing cost-efficient processes and significant capacity in setting up manufacturing plants for drugs satisfying international quality norms. India supplies medicines not only to other developing countries but also to developed countries such as the US. One of the most important factors contributing to this remarkable development was the abolition of product patent protection for pharmaceuticals in 1972. After independence, wanting to develop a pharmaceutical industry, India had invited multinational corporations (MNCs) to help develop the industry. Before 1972, although not keen to manufacture pharmaceuticals in India, they had used their patent rights to prevent Indian companies from doing so. As a result, in this period the industry remained underdeveloped, while at the same time multinationals’ monopolies led to high prices.]

Published: Nov 6, 2015

Keywords: World Trade Organization; Tenofovir Disoproxil Fumarate; Indian Company; Patent Protection; Compulsory License

There are no references for this article.